Serum KL-6 levels in patients with pulmonary complications after allogeneic bone marrow transplantation

International Journal of Hematology

Volumn 74, Issue 4, 2001, Pages 464-468

  Ashida, Takashi ^a   Higashishiba, Masaki ^a   Sumimoto, Yoshiyasu ^a   Sano, Tetsuaki ^a   Miyazato, Hajime ^a   Shimada, Takahiro ^a   Miyatake, Junichi ^a   Kawanishi, Kazunobu ^a   Tatsumi, Yoichi ^a   Kanamaru, Akihisa ^a  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Bone marrow transplantation; Interstitial pneumonia; KL 6

Indexed keywords

ANTIGEN; BIOLOGICAL MARKER; GLYCOPROTEIN; MUC1 PROTEIN, HUMAN; MUCIN; TUMOR ANTIGEN;

ADOLESCENT; ADULT; ALLOTRANSPLANTATION; ARTICLE; BLOOD; BLOOD DISEASE; BONE MARROW TRANSPLANTATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG DISEASE; MALE; METABOLISM; MIDDLE AGED;

ADOLESCENT; ADULT; ANTIGENS; ANTIGENS, NEOPLASM; BIOLOGICAL MARKERS; BONE MARROW TRANSPLANTATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GLYCOPROTEINS; HEMATOLOGIC NEOPLASMS; HUMANS; LUNG DISEASES; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; MUCINS; TRANSPLANTATION, HOMOLOGOUS;

EID: 0035748699     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02982094     Document Type: Article

References (18)

1. Meyers JD, Flournoy N, Thomas ED. Non-bacterial pneumonitis after allogeneic bone marrow transplantation: a review of ten year's experience. Rev Infect Dis. 1982;4:1119-1132.
2. Weiner RS, Bortin MM, Gale RR, et al. Risk factors associated with interstitial pneumonitis following allogeneic bone marrow transplantation. Transplant Proc. 1985;17:470-474.
3. Piedbois P, Cordonnier C, Levy C, et al. Diffuse interstitial pnemonitis following BMT: incidence and relationship with parameters of single fraction TBI. Bone Marrow Transplant. 1990;3(suppl 1):273.
4. Kohno N, Kyoizumi S, Awaya Y, et al. New serum indicator of interstitial pneumonitis activity: sialylated carbohydrate antigen KL-6. Chest. 1989;96:68-73.
5. Kohno N, Awaya Y, Oyama T, et al. KL-6, mucin-like glycoprotein, in bronchoalveolar lavage fluid from patients with interstitial lung disease. Am Rev Respir Dis. 1993;148:637-642.
6. Kobayashi J, Kitamura S. KL-6: a serum marker for interstitial pneumonia. Chest. 1995;108:311-315.
7. Kohno N, Akiyama M, Kyoizumi S, et al. A novel method for screening monoclonal antibodies reacting with antigenic determinants on soluble antigens: a reversed indirect enzyme-linked immunosorbent assay (RI-ELISA). Hiroshima J Med Sci. 1987;36:319-323.
8. Kobayashi J, Itoh Y, Kitamura S, et al. Establishment of reference intervals and cut-off value by an enzyme immunoassay for KL-6 antigen, a new marker for interstitial pneumonia. Jpn J Clin Pathol. 1996;44:653-658.
9. Turner-Warwick M, Burrows B, Johnson A. Cryptogenic fibrosing alveolitis: clinical features and their influence on survival. Thorax. 1980;35:171-180.
10. DeRemee RA. Serum lactic dehydrogenase activity and diffuse interstitial pneumonitis. MAM. 1968;204:1193-1195.
11. Crystal RG, Bitterman PB, Rennard SI, et al. Interstitial lung diseases of unknown cause: disorders characterized by chronic inflam-mation of the lower respiratory tract. N Engl J Med. 1984;310: 154-166.
12. Kohno N, Akiyama M, Kyoizumi S, et al. Detection of soluble tumor-associated antigens in sera and effusions using novel monoclonal antibodies, KL-3 and KL-6, against lung adenocarcinoma. Jpn J Clin Oncol. 1988;18:203-216.
13. Hamada H, Kohno N, Hiwada K. A new serum tumor marker, CAM 123-6, highly specific to pulmonary adenocarcinoma. Jpn J Cancer Res. 1994;85:211-219.
14. Stahel RA, Gilks WR, Lehmann HP, et al. Third international workshop on lung tumor and differentiation antigens: overview of the results of the central data analysis. Int J Cancer. 1994;8(suppl):6-26.
15. Kohno N, Inoue Y, Hamada H, et al. Difference in sero-diagnostic values among KL-6-associated mucins classified as Cluster 9. Int J Cancer. 1994;8(suppl):81-83.
16. Sato S, Nagaoka T, Hasegawa M, et ai. Elevated serum KL-6 levels inpatients with systemic sclerosis: association with the severity of pulmonary fibrosis. Dermatology. 2000;200:196-201.
17. Yamane K, Ihn H, Kubo M, et al. Serum levels of KL-6 as a useful marker for evaluating pulmonary fibrosis in patients with systemic sclerosis. J Rheumatol. 2000;27:930-934.
18. Nakajima H, Harigai M, Hara M, et al. KL-6 as a novel serum marker for interstitial pneumonia associated with collagen diseases. J Rheumatol. 2000;27:1164-1170.